Showing results (111-120 of 253) with videos related to

Sort By:
Pageof 26
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2014
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseasesAnna Guidetti, Carmelo Carlo-Stella, Silvia L Locatelli, et al.
European Journal of Hybrid Imaging|June 30, 2021
Methodological framework for radiomics applications in Hodgkin's lymphomaMartina Sollini, Margarita Kirienko, Lara Cavinato, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myelomaBachisio Ziccheddu, Claudia Giannotta, Mattia D'Agostino, et al.
International Journal of Radiation Oncology, Biology, Physics|March 15, 2016
Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter StudyMarco Ruella, Andrea Riccardo Filippi, Riccardo Bruna, et al.
Frontiers in Oncology|December 23, 2021
Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana LinfomiLaura Ballotta, Pier Luigi Zinzani, Stefano Pileri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2008
Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi surveyCorrado Tarella, Manuela Zanni, Michele Magni, et al.
Leukemia & Lymphoma|April 25, 2007
Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myelomaIgnazio Majolino, Marina Davoli, Ellen Carnevalli, et al.
Blood|March 1, 2007
Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantationFabio Ciceri, Chiara Bonini, Sarah Marktel, et al.
Blood|January 5, 2002
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignanciesPaolo Corradini, Corrado Tarella, Attilio Olivieri, et al.
British Journal of Haematology|November 14, 2013
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphomaMichelle Fanale, Sarit Assouline, John Kuruvilla, et al.
Pageof 26